Hereditary Breast and Ovarian Cancer (HBOC): Clinical Features and Counseling for BRCA1 and BRCA2, Lynch Syndrome, Cowden Syndrome, and Li-Fraumeni Syndrome

Obstetrics and Gynecology Clinics of North America

Volumn 37, Issue 1, 2010, Pages 109-133

  Shulman, Lee P ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

BRCA1 2; Genetic counseling; Hereditary breast cancer; Hereditary ovarian cancer; Lynch syndrome

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; MISMATCH REPAIR PROTEIN PMS2; PARATHYROID HORMONE RECEPTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; PROTEIN P53; PROTEIN PATCHED; UVOMORULIN;

CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GYNECOLOGIC CANCER; HEREDITARY BREAST AND OVARIAN CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HUMAN; MISMATCH REPAIR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

AGE FACTORS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; LI-FRAUMENI SYNDROME; OVARIAN NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 77952981208     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2010.03.003     Document Type: Review

References (61)

1. Lancaster J.M., Powell C.B., Kauff N.D., et al. SGO Committee Statement: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007, 107:159-162.
2. ACOG Practice Bulletin Hereditary breast and ovarian cancer syndrome. Gynecol Oncol 2009, 113:6-11.
3. Lynch H.T., Casey M.J., Snyder C.L., et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009, 3:97-137.
4. Kjaer S.K., Mellemkjaer L., Brinton L.A., et al. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65,000 sterilized women. Int J Epidemiol 2004, 33:596-602.
5. Palma M.D., Domchek S.M., Stopfer J., et al. The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res 2008, 68:7006-7014.
6. Bellosillio B., Tusquets I. Pitfalls and caveats in BRCA sequencing. Ultrastruct Pathol 2006, 30:229-235.
7. Whittemore A.S., Gong G., Imyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from 3 US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997, 60:496-504.
8. Risch H.A., McLaughlin J.R., Cole D.E.C., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a Kin-Cohort Study in Ontario, Canada. J Natl Cancer Inst 2006, 98:1694-1706.
9. Metcalfe K.A., Poll A., Royer R., et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 2010, 28:387-391.
10. Mikaelsdottir E.K., Valgeirsdottir S., Eyfjord J.E., et al. The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res 2004, 6:R284-R290.
11. Pal T., Permuth-Wey J., Sellers T.A. A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer. Cancer 2008, 113:733-742.
12. Wijnen J., de Leeuw W., Vasen H., et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999, 23:142-144.
13. Watson P., Vasen H.F.A., Mecklin J.-P., et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123:444-449.
14. Aaltonen L.A., Peltomaki P., Leach F.S., et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260:812-816.
15. Ramus S.J., Gayther S.A. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009, 3:138-150.
16. Bewtra C., Watson P., Conway T., et al. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992, 11:180-187.
17. Antoniou A.C., Gayther S.A., Stratton J.F., et al. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000, 18:173-190.
18. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers. J Natl Cancer Inst 2002, 94:1365-1372.
19. The Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91(15):1310-1316.
20. Risch H.A., McLaughlin J.R., Cole D.E.C., et al. Prevalence and penetrance in germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001, 68:700-710.
21. Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002, 8:3776-3781.
22. Levy-Lahad E., Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007, 96:11-15.
23. Mohammad H.B., Apffelstaedt J.P. Counseling for male BRCA mutation carriers-a review. Breast 2008, 17:441-450.
24. Ostrander E.A., Udler M.S. The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev 2008, 17:1843-1848.
25. Brose M., Rebbeck T., Calzone K., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a cancer risk evaluation program. J Natl Cancer Inst 2002, 94:1359-1365.
26. Mai P.L., Chatterjee N., Hartge P., et al. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate and pancreatic cancers, and melanoma. PLoS One 2009, 4(3):e4812. 10.1371/journal.pone.0004812.
27. Lynch H.T., Lynch P.M., Lanspa S.J., et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009, 76:1-18.
28. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA mismatch repair genes. Int J Cancer 1999, 81:214-218.
29. Banno K., Yanokura M., Kobayashi Y., et al. Endometrial cancer as a familial tumor: pathology and molecular carcinogenesis [review]. Curr Genomics 2009, 10:127-132.
30. Mathews K.S., Estes J.M., Connor M.G., et al. Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol 2008, 111:1161-1166.
31. Malander S., Rambech E., Kristoffersson U., et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006, 101:238-243.
32. Russo A., Calo V., Bruno L., et al. Hereditary ovarian cancer. Crit Rev Oncol Hematol 2009, 69:28-44.
33. Cederquist K., Emanuelsson M., Wiklund F., et al. Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet 2005, 68:533-541.
34. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-5788.
35. Jordan S.K., Siskind V., Green C., et al. Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 2010, 21:109-116.
36. Kurian A.W., Sigal B.M., Plevritis S.K. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010, 28:222-231.
37. U.S.Preventive Services Task Force Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005, 143:355-361.
38. Santen R.J., Boyd N.F., Chlebowski R.T., et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007, 14:169-187.
39. South S.A., Vance H., Farrell C., et al. Consideration of hereditary nonpolyposis colorectal cancer in BRCA mutation-negative familial ovarian cancers. Cancer 2009, 115:324-333.
40. Vasen H.F., Hendriks Y., de Jong A.E., et al. Identification of HNPCC by molecular analysis of colon and endometrial tumors. Dis Markers 2004, 20:207-213.
41. Resnick K.E., Hampel H., Fishel R., et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009, 114:128-134.
42. Goodfellow P.J., Buttin B.M., Herzog T.J., et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003, 100:5908-5913.
43. Hampel H., Panescu J., Lockman J., et al. Comment on: screening for Lynch syndrome (hereditary nonpolyposis colon cancer) among endometrial cancer patients. Cancer Res 2007, 62:9603.
44. Allain D.C. Genetic counseling and testing for common hereditary breast cancer syndromes. J Mol Diagn 2008, 10:383-395.
45. Orloff M.S., Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008, 27:5387-5397.
46. Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000, 37:828-830.
47. Shulman L.P. Advances in female hormonal contraception: current alternatives to oral regimens. Treat Endocrinol 2003, 2:247-256.
48. Lustbader E.D., Williams W.R., Bondy M.L., et al. Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 1992, 51:344-356.
49. Kinsler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
50. Knudson A.G. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001, 1:157-162.
51. Rahman N., Scott R.H. Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Hum Mol Genet 2007, 16(Spec No 1):R60-R66.
52. Fasching P.A., Gayther S., Pearce L., et al. Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009, 3:171-181.
53. Søegaard M., Frederiksen K., Jensen A., et al. Risk of ovarian cancer in women with first-degree relatives with cancer. Acta Obstet Gynecol Scand 2009, 88:449-456.
54. Prucka S.K., McIlvried D.E., Korf B.R. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example. Med Princ Pract 2008, 17:173-189.
55. Olaya W., Esquivel P., Wong J.H., et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg 2009, 198:562-565.
56. Spearman A.D., Sweet K., Zhou X.-P., et al. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 2008, 26:5393-5400.
57. Rantala J., Platten U., Lindgren G., et al. Risk perception after genetic counseling in patients with increased risk of cancer. Hered Cancer Clin Pract 2009, 7:15.
58. Caruso A., Vigna C., Marozzo B., et al. Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. J Exp Clin Cancer Res 2009, 28:157.
59. Phelps C., Bennett P., Jones H., et al. The development of a cancer genetic-specific measure of coping: the GRACE. Psychooncology 2009, 10.1002/pon.1629.
60. Morgan D., Sylvester H., Lucas F.L., et al. Perceptions of high-risk care and barriers to care among women at risk for hereditary breast and ovarian cancer following genetic counseling in the community setting. J Genet Couns 2009, 10.1007/s10897-009-9261-9.
61. Osako T., Horii R., Matsuura M., et al. High-grade breast cancers include both highly sensitive and highly resistant subsets to cytotoxic chemotherapy. J Cancer Res Clin Oncol 2010 Feb 9, [Epub ahead of print].